Telomir Pharmaceuticals, Inc. · NASDAQ:TELO
Telomir Pharmaceuticals — Bio Presentation (June 2025)
30 slides from Telomir Pharmaceuticals's conference presentation, June 2025
Slide 1: Designed to reverse cellular aging
Designed to reverse cellular aging... June 2025 Bio Presentation Nasdaq: TELO
Slide 2: Corporate Overview
CORPORATE OVERVIEW Progeria Research Wilson’s Disease Telomir Pharmaceuticals Inc. (Nasdaq: TELO) is a pre-clinical-stage pharmaceutical company leading the development of age-reversal science by focusing on addressing the root causes of age-related T E L O M I R P H A R M A . C O M conditions, rath
Slide 3: Telomir Management
TELOMIR MANAGEMENT Erez Aminov | Chairman & CEO Itzchak Angel, PhD | Chief Scientific Advisor § A biotechnology leader driving innovation in drug § Over 40 years of experience in guiding medical, development and strategic growth. pharmaceutical, drug, and business development in both large and emerg
Slide 4: Therapeutic Research Approaches for Telomir-1
THERAPEUTIC RESEARCH Investigating Telomir-1’s Explore the interactions APPROACHES T E L O M I R P H A R M A . C O M effects on copper and iron between iron, copper and FOR TELOMIR-1 regulation at the cellular level and in preclinical zinc on variable cellular functions focusing on models. cellular
Slide 5: Impact of Iron Overload
IMPACT OF IRON OVERLOAD Cellular § Oxidative stress § Mitochondrial dysfunction § DNA dysfunction § Ferroptosis § Cellular senescence T E L O M I R P H A R M A . C O M Functional § Accelerated aging § Senescence Pathology § Telomer shortening § Progeria and Werner § Insulin resistance syndromes § In
Slide 6: Impact of Iron and Copper Overload
Iron and copper overload contribute to AMD and retinal aging, while copper IMPACT OF IRON AND COPPER OVERLOAD overload is also central to Wilson’s disease and broader age-related neurodegenerative processes. IRON OVERLOAD COPPER OVERLOAD Accelerated T E L O M I R P H A R M A . C O M Aging Alzheimer’
Slide 7: Therapeutic Areas
THERAPEUTIC AREAS Key ongoing initiatives include: Wilson’s Disease Study Investigating Telomir-1’s effects on copper regulation in preclinical models. Type 2 Diabetes Studies Progeria and Werner syndrome Research T E L O M I R P H A R M A . C O M Building on zebrafish success, Telomir Following pro
Slide 8: Pre-Clinical Research: Age Reversal and Increased Longevity
Our molecule, Telomir-1 can effectively bind and chelate several ions. It has high affinity for PRE-CLINICAL RESEARCH iron and copper and lower affinity for zinc. Age Reversal and Increased Longevity T E L O M I R P H A R M A . C O M White: Hydrogen Blue: Nitrogen Gray: Carbon Orange: Metal Investor
Slide 9: Pre-Clinical Research: Age Reversal and Increased Longevity
PRE-CLINICAL RESEARCH Age Reversal and Increased Longevity Telomir-Zn, a lipophilic form of Telomir-1, readily enters cells and leverages its higher affinity for iron and copper over zinc to exchange harmful iron or copper ions with beneficial zinc. This exchange mechanism allows Telomir-Zn to chela
Slide 10: What Are Telomeres?
WHAT ARE TELOMERES? Age Reversal and Increased Longevity Telomeres are the protective end caps of a chromosome made up of DNA sequences and proteins (TTAGGG). Female Male XX XY T E L O M I R P H A R M A . C O M § Telomeres protect chromosome ends during cell division, preventing gene Genetic loss, l
Slide 11: Telomir-1 Restores Telomere Length in Accelerated Aging Models
Telomir-1 Restores Telomere Length in Accelerated Aging Models Telomir-1 reverses telomere shortening and restores length beyond wild-type levels in models mimicking Progeria and Werner syndromes. Reversal by Telomir-1 of shortened telomer length in an accelerated aging model in zebra fish Study Mod
Slide 12: Pre-Clinical Research: Age Reversal and Increased Longevity
High-dose Telomir-1 significantly extended nematode PRE-CLINICAL RESEARCH lifespan by ~2.5 days, demonstrating a strong longevity effect. Age Reversal and Increased Longevity Study Overview This preclinical study, in collaboration with Nagi Bioscience, used an in vivo microfluidic-based assay to eva
Slide 13: Pre-Clinical Research: Study in Adult Progeria
PRE-CLINICAL RESEARCH Age Reversal and Increased Longevity Study in Adult Progeria - Summary and Methodology The preclinical study with Nagi Bioscience SA used C. elegans with a wrn-1 gene mutation, the human equivalent of which is linked to Werner Syndrome (Adult Progeria), showing reduced life exp
Slide 14: Telomir-1 Reverses Key Aging Markers in Werner Syndrome Model
Telomir-1 Reverses Key Aging Markers in Werner Telomer length normalization Syndrome Model Telomere length and DNA methylation patterns were normalized in Sen57wrn⁻/⁻ zebrafish—exceeding wild-type levels at higher doses. • Mutant zebrafish showed severe telomere shortening T E L O M I R P H A R M A
Slide 15: Telomir-1 Restores Physical and Cellular Health in Werner Syndrome Model
Restauration of lost muscle weight Telomir-1 Restores Physical and Cellular Health in Werner Syndrome Model 14-day oral treatment reverses muscle loss and oxidative stress in Sen57wrn⁻/⁻ zebrafish • Mutant fish displayed significant loss of body and T E L O M I R P H A R M A . C O M muscle mass • Te
Slide 16: Telomir-1 Achieves Full Survival and Broad Rejuvenation in Werner Model
Telomir-1 Achieves Full Survival and Broad Rejuvenation in Werner Syndrome Model 14-day treatment in Sen57wrn⁻/⁻ zebrafish reverses aging hallmarks and eliminates mortality Survival analysis – no animals died when treated with telomir-1 Study Model & Design • Model: Sen57wrn⁻/⁻ND6⁻/⁺ zebrafish T E L
Slide 17: Pre-Clinical Research: Reversal of Key Type 2 Diabetes Parameters
Reversal of insulin resistance (HOMA-IR) PRE-CLINICAL RESEARCH Reversal of Key Type 2 Diabetes Parameters Study Overview and Results In collaboration with Pentagrit, Telomir evaluated two forms of Telomir-1, administered orally at three different doses, in zebrafish models of Type 2 diabetes mellitu
Slide 18: Significant Anti-Cancer Activity in Prostate Cancer Model
PRE-CLINICAL RESEARCH Significant Anti-Cancer Activity in Prostate Cancer Model Telomir-1 Demonstrates Promising Efficacy in Aggressive Human Prostate Cancer Model T E L O M I R P H A R M A . C O M Key Study Highlights: Model Used: Preclinical in vivo study using human prostate cancer PC3 cells in m
Slide 19: Telomir-1 Restores Vision in AMD Model
Varying light response Telomir-1™ Restores Vision in AMD Model First Oral Therapy Showing Regenerative Effects in FDA- Surrogate AMD Model Study Overview • Model: 18-month-old Sen57wrn⁻/⁻ND6⁻/⁺ zebrafish — recapitulates dry AMD with central vision loss, retinal thinning, oxidative stress and ~15% mo
Slide 20: Telomir-1 Rebuilds Retinal Layers in AMD Model
Telomir-1™ Rebuilds Retinal Layers in AMD Model Percent retinal degeneration Telomir-1™ Restores Vision & Retinal Structure in AMD Model First Oral Therapeutic Showing Regenerative Effects in FDA-Surrogate-Driven Proof-of-Concept Structural Regeneration T E L O M I R P H A R M A . C O M • Marked imp
Slide 21: Telomir-1 Restores Neuromotor Function in Wilson's Disease Model
Telomir-1™ Restores Neuromotor Function in Wilson’s Disease Model Episodic tremor events Telomir-1™ Reverses Multi-Organ Dysfunction in Wilson’s Disease Model Dose-Dependent Reversal of Neurological, Hepatic & Renal Damage in ATP7B ⁻ /⁻ Zebrafish Study Overview • Model: ATP7B C271X⁻/⁻ zebrafish, rep
Slide 22: Telomir-1 Reverses Multi-Organ Dysfunction in Wilson's Disease Model
Telomir-1™ Reverses Multi-Organ Dysfunction in Wilson’s Disease Model Liver copper levels Dose-Dependent Reversal of Neurological, Hepatic & Renal Damage in ATP7B⁻/⁻ Zebrafish Hepatic & Renal Benefit • ~50% reduction in liver copper accumulation T E L O M I R P H A R M A . C O M • Histopathology sco
Slide 23: Pre-Clinical Research: Expanding Therapeutic Potential in Autism and Spasmodic Dysphonia
PRE-CLINICAL RESEARCH Telomir-1 Reverses Cellular Decline—Expanding Therapeutic Potential In Vitro Proof-of-Mechanism Supports Targets in Autism & Spasmodic Dysphonia Key Findings (Human Cell Lines) • Cell viability under stress, supporting resilience in dividing cell populations T E L O M I R P H A
Slide 24: Telomir-Ag2 First-in-Class Silver(II) Antimicrobial
PRE-CLINICAL RESEARCH Telomir-Ag₂ – First-in-Class Silver(II) Antimicrobial Breakthrough Preclinical Efficacy Against MRSA & Multidrug-Resistant Pathogens Strategic Rationale • Antimicrobial resistance is a top global health threat (e.g., MRSA causes 323K hospitalizations and >10K U.S. T E L O M I R
Slide 25: Anticipated Timeline for Telomir-1
ANTICIPATED TIMELINE FOR TELOMIR-1 2025 2025 2025 2025 T E L O M I R P H A R M A . C O M Q1 Q2 Q3 Q4 § GMP CMC (Chemistry, § CMC (Chemistry, § CMC (Chemistry, Manufacturing, and Manufacturing, and Controls): Manufacturing, and Controls): GMP (Good Synthesis, Upscaling & Controls): Stability, Manufac
Slide 26: Market Opportunity
MARKET OPPORTUNITY Summary of USEpidemiology The eligible patient pool analysis for Telomir-1 highlights a potential large patient pool looking for potential treatments to their conditions. T E L O M I R P H A R M A . C O M Total Eligible Total Diagnosed Treatment Population Addressable Prevalence R
Slide 27: Market Opportunity for Rare Diseases
MARKET OPPORTUNITY FOR RARE DISEASES Summary of USEpidemiology The eligible patient pool analysis for Telomir-1 highlights a potential large patient pool looking for potential treatments to their conditions. T E L O M I R P H A R M A . C O M Total Eligible Total Diagnosed Population Treatment Rate A
Slide 28: Growth Strategy
GROWTH STRATEGY Continue pre-clinical development of Telomir-1 across a range of diseases and progress into clinical development T E L O M I R P H A R M A . C O M Advance Telomir-1 through clinical development and FDA approval Identify additional product candidates and expand current candidates into
Slide 29: Investment Highlights
INVESTMENT HIGHLIGHTS Telomir-1 T E L O M I R P H A R M A . C O M TELOMIR-1 is novel Based on our pre- The Company’s goal is small molecule metal clinical studies to date to explore the potential ion regulator, with a we assemble of Telomir-1 starting broad potential to experimental evidences with o
Slide 30: Thank you
Thank 100 SE 2nd Street you. Suite 2000 #1009 Miami, FL 33131 TelomirPharma.com
Telomir Pharmaceuticals — Bio Presentation (June 2025) on 6ix